LACTOSE MONOHYDRATE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 342.0 | -5.4 | 8 | 11 | 190.0 | 4 | 1.0 |
- CAS
- 64044515
- UNII
- EWQ57Q8I5X
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 32 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00888680 | Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine | Phase 2 | Terminated | |
| NCT02097706 | 2015-01-01 | A Novel Cognitive Enhancing Drug for Borderline Personality Disorder | Phase 4 | Recruiting |
| NCT02117661 | 2015-01-01 | Carnitine for the Treatment of Atherosclerosis. | Phase 2 | Recruiting |
| NCT02326350 | 2015-01-01 | ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial | Phase 2 | Enrolling By Invitation |
| NCT01550107 | 2014-12-01 | Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength' | Phase 4 | Enrolling By Invitation |
| NCT02097589 | 2014-06-01 | The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23 | Phase 4 | Completed |
| NCT01644877 | 2014-03-01 | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen | Phase 2 | Recruiting |
| NCT02065076 | 2014-02-01 | Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients | Phase 4 | Completed |
| NCT01675986 | 2014-01-01 | Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score | Phase 2 | Recruiting |
| NCT02042521 | 2014-01-01 | A Dietary Supplement for Early Cigarette Withdrawal | Phase 2 | Recruiting |
| NCT01986582 | 2013-10-01 | NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis | Phase 2 | Recruiting |
| NCT01748279 | 2012-12-01 | The Effects of Atorvastatin Treatment in COPD Patients | Phase 4 | Completed |
| NCT01528800 | 2012-11-01 | Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients | Phase 2 | Recruiting |
| NCT01659307 | 2012-09-01 | The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury | Phase 2 | Recruiting |
| NCT01643187 | 2012-07-01 | Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children | Phase 2 | Not Yet Recruiting |
| NCT01602185 | 2012-05-01 | Study of NMDA Antagonists and Neuropathic Pain | Phase 2 | Recruiting |
| NCT01536314 | 2012-02-01 | Prophylaxis of Neuropathic Pain by mémantine | Phase 3 | Completed |
| NCT01575678 | 2012-01-01 | The Effect of Melatonin on Nocturnal Enuresis | Phase 2 | Recruiting |
| NCT02214095 | 2012-01-01 | Glucosamine Periodontal Adjunctive Therapy | Phase 0 | Terminated |
| NCT01504867 | 2012-01-01 | LIPS-A: Lung Injury Prevention Study With Aspirin | Phase 2 | Recruiting |
| NCT01320345 | 2011-09-01 | A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume | Phase 3 | Not Yet Recruiting |
| NCT01400906 | 2011-07-01 | Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics. | Phase 2 | Completed |
| NCT01404754 | 2011-03-01 | Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers | Phase 1 | Enrolling By Invitation |
| NCT01127126 | 2010-12-01 | Bryophyllum Versus Placebo for Overactive Bladder | Phase 2 | Completed |
| NCT01277237 | 2010-09-01 | The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease | Phase 3 | Completed |
| NCT01190683 | 2010-08-01 | Vitamin D and Muscle Strength and Surface (Electromyography) EMG | Phase 3 | Completed |
| NCT01113567 | 2010-07-01 | Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy | Phase 3 | Recruiting |
| NCT01098318 | 2010-06-01 | Rhodiola Rosea Therapy of Major Depressive Disorder | Phase 3 | Completed |
| NCT01151306 | 2010-06-01 | The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Completed |
| NCT01136317 | 2010-04-01 | Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects | Phase 2 | Completed |
| NCT01040429 | 2010-02-01 | The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial | Phase 2 | Completed |
| NCT01074554 | 2010-02-01 | Trial of Antimycobacterial Therapy in Sarcoidosis | Phase 1/Phase 2 | Active, Not Recruiting |
| NCT01041755 | 2009-12-01 | Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. | Phase 4 | Completed |
| NCT01099332 | 2009-11-01 | Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease | Phase 1/Phase 2 | Active, Not Recruiting |
| NCT01014338 | 2009-10-01 | Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Completed |
| NCT00979056 | 2009-10-01 | Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin | Phase 3 | Completed |
| NCT00876161 | 2009-04-01 | DAS181 Single Dose Escalation Study in Healthy Adults | Phase 1 | Completed |
| NCT00850460 | 2009-02-01 | Quality of Life in Patients With Statin-Associated Myopathy | Phase 4 | Terminated |
| NCT00841230 | 2009-02-01 | Deanxit and Rivotril in Tinnitus Patients | Phase 4 | Completed |
| NCT01269892 | 2009-01-01 | Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea | Phase 2 | Completed |
| NCT00755950 | 2008-10-01 | Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis | Phase 2/Phase 3 | Terminated |
| NCT00682214 | 2008-05-01 | Cholecalciferol Supplementation, Muscle Strength | Phase 1 | Completed |
| NCT00507000 | 2008-05-01 | Pulmonary Tuberculosis and Vitamin D | Phase 3 | Active, Not Recruiting |
| NCT00624754 | 2008-03-01 | Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT | Phase 2 | Completed |
| NCT00626275 | 2007-10-01 | Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Subjects With Rheumatoid Arthritis | Phase 2 | Completed |
| NCT00403923 | 2007-04-01 | Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative Colitis | Phase 0 | Completed |
| NCT00351117 | 2007-03-01 | St. John's Wort in the Treatment of Raynaud's Phenomenon | Phase 3 | Completed |
| NCT00361543 | 2006-08-01 | Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia | Phase 4 | Completed |
| NCT00504946 | 2005-09-01 | Pharmacological Modulations of Allergen-Specific Immunotherapy | Phase 3 | Completed |
| NCT00149630 | 2005-01-01 | Pharmacogenetics of Disulfiram for Cocaine | Phase 2 | Completed |
| NCT00090064 | 2004-03-01 | A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder | Phase 2 | Completed |
| NCT02172508 | 2004-01-01 | Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation | Phase 4 | Terminated |
| NCT00902616 | 2003-06-01 | Effect of Arginine on Microcirculation in Patients With Diabetes | Phase 4 | Completed |
| NCT02175342 | 1998-03-01 | Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed |
(Browse) Purchasable Analogs in ZINC
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Buccal | Tablet | 21.38MG |
| Im - Iv | Injection | 1.25% |
| Im - Iv | Powder | 2.75% |
| Im - Iv | Powder, For Injection Solution | 2.5% |
| Im - Iv - Sc | Powder, For Injection Solution, Lyophilized | 10.7% |
| Im - Sc | Injection | 2.1% |
| Inhalation | Powder, For Inhalation | 62% |
| Intracavitary | Powder, For Injection Solution, Lyophilized | 4.54% |
| Intramuscular | Injection | 5% |
| Intramuscular | Powder, For Injection Solution | 10.7% |
| Intramuscular | Powder, For Injection Solution, Lyophilized | 1.05% |
| Intravenous | Injection | 4.5%W/V |
| Intravenous | Injection | 25% |
| Intravenous | Powder, For Injection Solution | 10.7% |
| Intravenous | Powder, For Injection Solution | 75% |
| Intravenous | Powder, For Injection Solution, Lyophilized | 69% |
| Iv - Sc | Injection | 4.9% |
| Iv(Infusion) | Injectable | 4.5%W/V |
| Iv(Infusion) | Powder, For Injection Solution | 20% |
| Iv(Infusion) | Powder, For Injection Solution, Lyophilized | 4.75%W/V |
| Iv(Infusion) | Powder, For Injection Suspension, Lyophilized | 10.2%W/V |
| Oral | Capsule | 427.26MG |
| Oral | Capsule | 430.42MG |
| Oral | Capsule (Immed./comp. Release) | 112MG |
| Oral | Capsule (Immed./comp. Release), Hard Gelatin | 166.77MG |
| Oral | Capsule, Coated Pellets | 33.09MG |
| Oral | Capsule, Coated, Hard Gelatin | 85MG |
| Oral | Capsule, Coated, Soft Gelatin | 178.91MG |
| Oral | Capsule, Delayed Action | 125.09MG |
| Oral | Capsule, Delayed Action, Enteric Coated, Hard Gelatin | 76.4MG |
| Oral | Capsule, Enteric Coated Pellets | 100MG |
| Oral | Capsule, Extended Release | 536.4MG |
| Oral | Capsule, Hard Gelatin | 199.5MG |
| Oral | Capsule, Hard Gelatin | 141MG |
| Oral | Capsule, Sustained Action | 67MG |
| Oral | Capsule, Sustained Action | 147.6MG |
| Oral | Capsule, Sustained Action, Hard Gelatin | 18.8MG |
| Oral | Dispersible Tablet | 543.6MG |
| Oral | Granule | 109.8MG |
| Oral | Granule, For Suspension | |
| Oral | Powder, For Inhalation | 2.5% |
| Oral | Powder, For Suspension | |
| Oral | Tablet | 180MG |
| Oral | Tablet | 696.3MG |
| Oral | Tablet | 708.9MG |
| Oral | Tablet | 455MG |
| Oral | Tablet (Immed./comp. Release), Coated | 254MG |
| Oral | Tablet (Immed./comp. Release), Film Coated | 269.8MG |
| Oral | Tablet (Immed./comp. Release), Uncoated, Chewable | 62.3MG |
| Oral | Tablet (Immed./comp. Release), Uncoated, Chewable | 100MG |
| Oral | Tablet, Chewable | 98.67MG |
| Oral | Tablet, Coated | 346.5MG |
| Oral | Tablet, Coated | 186MG |
| Oral | Tablet, Controlled Release | 152.75MG |
| Oral | Tablet, Delayed Action | 385.55MG |
| Oral | Tablet, Delayed Action, Enteric Coated | 157.95MG |
| Oral | Tablet, Delayed Action, Enteric Coated | 88.5MG |
| Oral | Tablet, Delayed Release | 30MG |
| Oral | Tablet, Enteric Coated Particles | 150MG |
| Oral | Tablet, Extended Release | 538MG |
| Oral | Tablet, Extended Release | 43.23MG |
| Oral | Tablet, Film Coated | 587.44MG |
| Oral | Tablet, Film Coated | 556MG |
| Oral | Tablet, For Suspension | 4.9MG |
| Oral | Tablet, Multilayer, Coated | 22.7MG |
| Oral | Tablet, Orally Disintegrating | 145.2MG |
| Oral | Tablet, Repeat Action | 155.28MG |
| Oral | Tablet, Sustained Action | 299.2MG |
| Oral | Tablet, Sustained Action | 156.8MG |
| Oral | Tablet, Sustained Action, Coated | 215MG |
| Oral | Tablet, Sustained Action, Coated | 83.3MG |
| Oral | Tablet, Sustained Action, Film Coated | 260MG |
| Oral | Tablet, Sustained Release, Film Coated | 81.9MG |
| Oral-21 | Tablet | 83.65MG |
| Oral-21 | Tablet | 48MG |
| Oral-21 | Tablet, Coated | 35.19MG |
| Oral-28 | Tablet | 93.87MG |
| Oral-28 | Tablet | 39.62MG |
| Oral-28 | Tablet, Coated | 82.89MG |
| Oral-28 | Tablet, Film Coated | 65.37MG |
| Respiratory (Inhalation) | Powder, For Inhalation | 2% |
| Subcutaneous | Powder, For Injection Solution | 10.7% |
| Sublingual | Tablet | 191.76MG |
| Sublingual | Tablet | 164.38MG |
| Sublingual | Tablet (Immed./comp. Release), Uncoated, Buccal | 160.4MG |
| Vaginal | Emulsion, Cream | |
| Vaginal | Insert | 760.5MG |
| Vaginal | Tablet | 760.5MG |
| Vaginal | Tablet | 596MG |
| Vaginal | Tablet, Film Coated | 17.9MG |